載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.89
−US$0.0256 · -2.80%
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
一般交易時段
US$0.89
−US$0.0256 · -2.80%
盤中時間採用ET。市場資料可能有所延遲。
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
日內區間
目前US$0.89
52週區間
目前US$0.89
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
49
合理估值
情緒
55
多空交錯
風險
85
極高風險
動能
27
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
日內區間
目前US$0.89
52週區間
目前US$0.89
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 100.55萬 USD | 60.76萬 USD | 25.36萬 USD | 22.32萬 USD | 116.03萬 USD |
| 銷貨成本 | 78.17萬 USD | 38.48萬 USD | 47.46萬 USD | 43.24萬 USD | 85.07萬 USD |
| 毛利 | 22.38萬 USD | 22.28萬 USD | −22.1萬 USD | −20.92萬 USD | 30.96萬 USD |
| 研究與開發 | 210.62萬 USD | 498.65萬 USD | 69.18萬 USD | 52.56萬 USD | 551.09萬 USD |
| 銷售、一般及管理費用 | 627.98萬 USD | 502.5萬 USD | 424.18萬 USD | 130.37萬 USD | 111.54萬 USD |
| 營業費用 | 798.24萬 USD | 993.77萬 USD | 493.36萬 USD | 154.13萬 USD | 143.37萬 USD |
| 利息支出 | 7805 USD | 7912 USD | 228.66萬 USD | 398.94萬 USD | 317.27萬 USD |
| 折舊和攤銷 | 8.29萬 USD | 6.37萬 USD | 10.04萬 USD | 7.88萬 USD | 7.18萬 USD |
| 營業利益 | −775.86萬 USD | −971.49萬 USD | −515.46萬 USD | −175.04萬 USD | −112.41萬 USD |
| 淨利 | −736.83萬 USD | −794.71萬 USD | −376.57萬 USD | −618.17萬 USD | −425.17萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
